ARCHIVES

Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction.

This article is from The Cancer Letter archive.

Vol. 32 No. 15 | April 21, 2006

Download PDF Visit The Full Archive

Related Articles

NCI Programs: Coleman To Lead NCI’s New Radiation Oncology Program

February 5, 1999

FDA Grants Accelerated Approval To Mekinist-Tafinlar Combination

January 31, 2014

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

November 26, 2010

ODAC Recommends Approval of Gemcitabine For Pancreatic Cancer

August 4, 1995

Large Bowel Study Expansion Hampered By Lack Of Coordination, NCI Admits

May 17, 1974

Strict System For Protection Of Human Subjects Ordered In Wake Of NIH Investigation

August 9, 1991